Table 3.
US Emergency Department (ED) Visits for Adverse Drug Events (ADEs) From the Most Commonly Implicated Drug Products by Patient Age, 2013-2014a
| Drug Product | ED Visits for ADEs | |
|---|---|---|
| No. of Cases | National Estimate, % (95% CI)b | |
| All Patients (N = 42 585) | ||
| Warfarin | 6179 | 15.1 (12.3-17.9) |
| Insulin | 4859 | 10.7 (8.6-12.7) |
| Clopidogrel | 1778 | 4.4 (2.9-5.9) |
| Amoxicillin | 1780 | 3.8 (3.3-4.3) |
| Aspirin | 1518 | 3.5 (2.2-4.9) |
| Sulfamethoxazole-trimethoprim | 1152 | 3.2 (2.7-3.7) |
| Lisinopril | 1096 | 2.4 (1.8-3.0) |
| Metformin | 766 | 1.7 (1.4-2.1) |
| Ibuprofen | 722 | 1.6 (1.3-2.0) |
| Rivaroxaban | 526 | 1.3 (0.8-1.8) |
| Acetaminophen-hydrocodone | 492 | 1.3 (1.0-1.6) |
| Cephalexin | 431 | 1.2 (0.9-1.5) |
| Acetaminophen-oxycodone | 459 | 1.1 (0.8-1.4) |
| Acetaminophen | 479 | 1.0 (0.8-1.2) |
| Amoxicillin-clavulanate | 422 | 1.0 (0.9-1.2) |
| Patients Aged ≤19 y (n = 5981)c | ||
| Amoxicillin | 1264 | 21.5 (19.8-23.1) |
| Sulfamethoxazole-trimethoprim | 244 | 5.3 (3.9-6.7) |
| Ibuprofen | 173 | 3.6 (2.7-4.5) |
| Azithromycin | 128 | 3.0 (2.5-3.6) |
| Amoxicillin-clavulanate | 186 | 2.9 (2.3-3.5) |
| Cefdinir | 153 | 2.6 (1.4-3.8) |
| Cephalexin | 120 | 2.5 (1.7-3.3) |
| Insulin | 106 | 1.7 (1.1-2.3) |
| Acetaminophen | 81 | 1.6 (1.0-2.1) |
| Clindamycin | 88 | 1.3 (0.9-1.8) |
| Penicillin | 49 | 1.1 (0.6-1.5) |
| Influenza vaccine | 58 | 1.0 (0.6-1.4) |
| Methylphenidate | 51 | 0.9 (0.6-1.3) |
| Diphenhydramine | 52 | 0.9 (0.5-1.3) |
| Risperidone | 50 | 0.9 (0.4-1.3) |
| Patients Aged ≥65 y (n = 13 636) | ||
| Warfarin | 4397 | 31.9 (27.6-36.2) |
| Insulin | 1950 | 13.0 (10.3-15.8) |
| Clopidogrel | 1373 | 9.9 (7.3-12.5) |
| Aspirin | 1052 | 7.1 (4.0-10.2) |
| Rivaroxaban | 412 | 2.9 (2.1-3.8) |
| Lisinopril | 380 | 2.6 (1.9-3.3) |
| Metformin | 373 | 2.6 (2.0-3.2) |
| Glipizide | 295 | 1.8 (1.3-2.4) |
| Sulfamethoxazole-trimethoprim | 153 | 1.4 (1.1-1.7) |
| Dabigatran | 154 | 1.2 (0.7-1.7) |
| Acetaminophen-hydrocodone | 131 | 1.1 (0.8-1.4) |
| Metoprolol | 105 | 1.0 (0.7-1.3) |
| Enoxaparin | 179 | 1.0 (0.7-1.3) |
| Glyburide | 131 | 1.0 (0.7-1.3) |
| Glimepiride | 132 | 0.9 (0.6-1.2) |
Data are from the National Electronic Injury Surveillance System–Cooperative Adverse Drug Event Surveillance project, US Centers for Disease Control and Prevention. Data exclude ED visits for abuse or self-harm. Drug products are not mutually exclusive; for some ED visits, more than 1 drug product was implicated in the ADE. Drugs that were not identified at the active ingredient level (eg, unnamed antibiotic or unknown drug) are not shown.
Calculated from statistical weighting of cases based on the sample design. National estimates may vary for similar Nos. of cases because of statistical weighting.
Excludes ED visits for unsupervised medication ingestions by children aged 10 years or younger.